| Dr William H Forlano, MD | |
|
119 Holland Circle Dr, Amsterdam, NY 12010-7550 | |
| (518) 843-4522 | |
| (518) 843-4522 |
| Full Name | Dr William H Forlano |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 119 Holland Circle Dr, Amsterdam, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114928413 | NPI | - | NPPES |
| 02426593 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 228576 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna Home Health | Albany, NY | Home health agency |
| St Mary's Healthcare | Amsterdam, NY | Hospital |
| Nathan Littauer Hospital | Gloversville, NY | Hospital |
| Saratoga Hospital | Saratoga springs, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carondelet Regional Medical Pc | 0840554051 | 13 |
News Archive
Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong.
Vanda Pharmaceuticals Inc., today announced financial and operational results for the third quarter ended September 30, 2014.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.
Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.
› Verified 7 days ago
| Entity Name | Amsterdam Family Practice Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750307039 PECOS PAC ID: 5193725190 Enrollment ID: O20061221000369 |
News Archive
Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong.
Vanda Pharmaceuticals Inc., today announced financial and operational results for the third quarter ended September 30, 2014.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.
Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.
› Verified 7 days ago
| Entity Name | Carondelet Regional Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861939944 PECOS PAC ID: 0840554051 Enrollment ID: O20180515002257 |
News Archive
Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong.
Vanda Pharmaceuticals Inc., today announced financial and operational results for the third quarter ended September 30, 2014.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.
Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William H Forlano, MD 119 Holland Circle Dr, Amsterdam, NY 12010-7550 Ph: (518) 843-4522 | Dr William H Forlano, MD 119 Holland Circle Dr, Amsterdam, NY 12010-7550 Ph: (518) 843-4522 |
News Archive
Even before media reports and a congressional hearing vilified Valeant Pharmaceuticals International for raising prices on a pair of lifesaving heart drugs, Dr. Umesh Khot knew something was very wrong.
Vanda Pharmaceuticals Inc., today announced financial and operational results for the third quarter ended September 30, 2014.
Researchers at the University of California, San Diego have used a new strategy to identify differences between non-metastatic and highly metastatic breast cancer cells. The article by Valerie Montel et al., "Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model," appears in the May 2005 issue of The American Journal of Pathology and is accompanied by a commentary.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.
Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.
› Verified 7 days ago
Jessica Lee Benoit, FNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 5010 Ny-30, Amsterdam, NY 12010 Phone: 518-842-0017 | |
Dr. Robert M Droege, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 119 Holland Circle Dr, Amsterdam, NY 12010 Phone: 518-843-4522 Fax: 518-843-8306 | |
Dr. Michael Angelo Rochet, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 380 Guy Park Ave, Amsterdam, NY 12010 Phone: 518-841-7415 Fax: 518-841-7417 | |
Dr. Mahmood A Khan, M.D., M.B.B.S, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5032 State Highway 30, Medical Plaza, Amsterdam, NY 12010 Phone: 518-842-0200 Fax: 518-842-3003 | |
Sabrina Michelle Bowie, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5010 State Highway 30, Ste 204, Amsterdam, NY 12010 Phone: 518-842-8185 Fax: 518-842-8189 | |
Dr. Peter F Diamond, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 119 Holland Circle Dr, Amsterdam, NY 12010 Phone: 518-843-4522 Fax: 518-843-8306 |